F8053

Anti-FADD antibody, Mouse monoclonal

Name: Anti-FADD antibody, Mouse monoclonal
Brand: SIGMA

clone FD19, purified from hybridoma cell culture

Synonym(s):

Anti-Fas Associated Death Domain

Select a Size

All Photos(1)

About This Item

UNSPSC Code:

12352203

NACRES:

NA.41

MDL number:

MFCD01633337

Product Name

Anti-FADD antibody, Mouse monoclonal, clone FD19, purified from hybridoma cell culture

biological source

mouse

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

FD19, monoclonal

form

buffered aqueous solution

mol wt

antigen ~28 kDa

species reactivity

human

concentration

~2 mg/mL

technique(s)

immunoprecipitation (IP): suitable
indirect ELISA: suitable
microarray: suitable
western blot: 0.5-1 μg/mL using total cell extracts of A431 cells

isotype

IgG1

UniProt accession no.

Q13158

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Application

Anti-FADD antibody, Mouse monoclonal has been used in:

immunoblotting
immunoprecipitation
enzyme-linked immunosorbent assay (ELISA)

Biochem/physiol Actions

FADD (Fas Associated Death Domain) is associated with various non-apoptotic cellular pathways such as regulation of cell cycle machinery in T lymphocytes connected to the phosphorylation state of FADD and to the FasL/TRAIL-induced transcriptional activation of c-fos protooncogene. It also interacts with the hepatitis C virus core protein in the HEK-293 cell line.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Anti-FADD antibody, Mouse monoclonal (mouse IgG1) is derived from the FD19 hybridoma produced by the fusion of murine myeloma cells (NS1) and splenocytes from mouse immunized with purified recombinant human FADD.

Immunogen

purified recombinant human FADD.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Not finding the right product?

Try our Product Selector Tool.

Storage Class

10 - Combustible liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A novel naphthyridine derivative, 3u, induces necroptosis at low concentrations and apoptosis at high concentrations in human melanoma A375 cells

Kong Q, et al.

International Journal of Molecular Sciences, 19(10), 2975-2975 (2018)

Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs

Huang Y, et al.

International Journal of Oncology, 49(1), 153-163 (2016)

A Novel Naphthyridine Derivative, 3u, Induces Necroptosis at Low Concentrations and Apoptosis at High Concentrations in Human Melanoma A375 Cells.

Qinghong Kong et al.

International journal of molecular sciences, 19(10) (2018-10-03)

Naphthyridine derivatives are a widely-used class of heterocycles due to their pharmacological activities. A novel compound (10-Methoxy-1,2,3,4-tetrahydrobenzo(g)(1,3) diazepino(1,2-a)-(1,8)naphthyridin-6-yl)(phenyl) methanone (named 3u), showed good anticancer activity in the human malignant melanoma cell line A375 via Thiazolyl Blue Tetrazolium Bromide (MTT) assay.

Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs.

Ying Huang et al.

International journal of oncology, 49(1), 153-163 (2016-05-24)

The discovery of the TRAIL protein and its death receptors DR4/5 changed the horizon of cancer research because TRAIL specifically kills cancer cells. However, the validity of TRAIL-based cancer therapies has yet to be established, as most cancer cells are

FADD-deficient T cells exhibit a disaccord in regulation of the cell cycle machinery.

J Zhang et al.

The Journal of biological chemistry, 276(32), 29815-29818 (2001-06-08)

FADD is an adapter protein that was originally isolated as a transducer of apoptotic signals for death domain-containing receptors. However, FADD-deficient mice are embryonic lethal and FADD(-/-) T cells developed from FADD(-/-) embryonic stem cells in the RAG-1(-/-) hosts lack

View All Related Papers